Bavarian Nordic A/S has announced that Health Canada has accepted its New Drug Submission for the review of its chikungunya vaccine candidate, CHIKV VLP. This marks a significant step in the company's efforts to expand global access to the vaccine, which has already received approvals in the US, EU, and UK. The submission is based on data from two successful phase 3 clinical trials involving over 3,500 participants, demonstrating high efficacy and safety. Pending approval, the vaccine could become available to Canadians seeking protection against chikungunya virus as early as the first half of 2026.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。